January 19th 2017

Publication news: Subcutaneous administration of methotrexate in psoriasis: Results from the METOP trial have been published

Data reporting the use of methotrexate for the treatment of moderate to severe psoriasis have largely been limited to oral administration. Subcutaneous administration has not been well characterized in this therapeutic area. Results from the METOP trial, reporting the use of an intensified dosing schedule (up to 22.5 mg/wk) of subcutaneous methotrexate for the treatment of psoriasis, have been published in The Lancet.